GCP Revision 3 Update
Sign up Free Webinar
Market Access Strategy
Sign up Free Webinar

Excellence in action, meet our team.

We prioritize transparency, swift communication, and competent guidance. Our commitment to excellence ensures that our clients receive informed support and achieve their objectives efficiently.

alt=""
GCP Revision 3 Update
Sign up Free Webinar
Market Access Strategy
Sign up Free Webinar

Excellence in action: meet our team.

We prioritize transparency, swift communication, and competent guidance. Our commitment to excellence ensures that our clients receive informed support and achieve their objectives efficiently.

Find us at a conference
alt=""
GCP Revision 3 Update
Sign up Free Webinar
Market Access Strategy
Sign up Free Webinar
alt=""

Excellence in action, meet our team.

We prioritize transparency, swift communication, and competent guidance. Our commitment to excellence ensures that our clients receive informed support and achieve their objectives efficiently.

alt=""

Pascal Winnen (MSc)
Chief Executive Officer/
Quality Assurance/
Board of Directors

LINKEDIN PROFILE

Mohamed Hussien (BPharm, PhD)
Chief Commercial Officer/
Neuroscience
g

LINKEDIN PROFILE

Maria Kuthning (MSc)
Head of Clinical Operations
.
.

LINKEDIN PROFILE

Cornelia Baumgartner- Diolaiuti
Clinical Operations Expert/
Oncology
.

LINKEDIN PROFILE

Gheorghe Nicusor Pop (Dr. Med)
Biostatician/
Medical Monitor
.

LINKEDIN PROFILE

Sandra Müller Lettlova (PhD)
Clinical Trial Manager/
Clinical Scientist
.

LINKEDIN PROFILE

Ossama Khalaf (BPharm, PhD)
Medical Writer/Grant Expert
.
.

LINKEDIN PROFILE

Franziska Stemmler
Business Development
.
.

LINKEDIN PROFILE

Gabriela Wesolowski
Sales
.
.

LINKEDIN PROFILE

Frank Stein (Prof. Dr. Dr. h.c.)
Senior Expert Quality &
Regulatory Affairs Medical Devices
.

LINKEDIN PROFILE

Dr. Frank Kramer
Clinical Operations Expert
Cardiology
.

LINKEDIN PROFILE

João Bocas
Wearable Devices Expert
.
.

LINKEDIN PROFILE

Clive Roper (BSc, PhD, CBiol, CSci, ERT, FRSB)
Toxicology Expert
.

LINKEDIN PROFILE

Cátia Moutinho
Medical Writer/
Single-Cell Technology
.

LINKEDIN PROFILE

Dr. Thorben Bonarius
Regulatory Affairs Expert Pharma- & Biotech
.

LINKEDIN PROFILE

Sanja Fitzgerald (Dr. Sc. ETH)
Market Access Strategy, Pricing & Reimbursement
.

LINKEDIN PROFILE

Ivana Krešić
Digital Media
.
.

LINKEDIN PROFILE

Juan Ruiz (MFA)
Graphic Design
.
.

LINKEDIN PROFILE

Dr. Arthur Redpath (BVM&S MRCVS MCIM)
Animal Health Business Development Leader

LINKEDIN PROFILE

Dr. Stefan Stübinger
Innovation & Medical Advisor Cranio-Maxillofacial and Dental Implant Expert
.

LINKEDIN PROFILE

Paul Hadvary (Dr. scnat ETH)
Chairman/
Board of Directors
.

LINKEDIN PROFILE

Ricardo Cordero (Dr. oec HSG)
Board of Directors
.
.

LINKEDIN PROFILE

Peter Huber
Board of Directors
.
.

LINKEDIN PROFILE

Ralf Schumacher
Board of Directors
.
.

LINKEDIN PROFILE
alt=""

Pascal Winnen (MSc)
Chief Executive Officer/
Quality Assurance/
Board of Directors

LINKEDIN PROFILE

Mohamed Hussien (BPharm, PhD)
Chief Commercial Officer/
Neuroscience

LINKEDIN PROFILE

Maria Kuthning (MSc)
Head of Clinical Operations
.
.

LINKEDIN PROFILE

Cornelia Baumgartner- Diolaiuti
Clinical Operations Expert/
Oncology

LINKEDIN PROFILE

Gheorghe Nicusor Pop (Dr. Med)
Biostatician/
Medical Monitor

LINKEDIN PROFILE

Sandra Müller Lettlova (PhD)
Clinical Trial Manager/
Clinical Scientist
.

LINKEDIN PROFILE

Ossama Khalaf (BPharm, PhD)
Medical Writer/Grant Expert
.

LINKEDIN PROFILE

Franziska Stemmler
Business Development
.
.

LINKEDIN PROFILE

Gabriela Wesolowski
Sales
.
.

LINKEDIN PROFILE

Frank Stein (Prof. Dr. Dr. h.c.)
Senior Expert Quality &
Regulatory Affairs Medical Devices

LINKEDIN PROFILE

Dr. Frank Kramer
Clinical Operations Expert
Cardiology
.

LINKEDIN PROFILE

João Bocas
Wearable Devices Expert
.
.

LINKEDIN PROFILE

Clive Roper (BSc, PhD, CBiol, CSci, ERT, FRSB)
Toxicology Expert
.

LINKEDIN PROFILE

Cátia Moutinho
Medical Writer/
Single-Cell Technology
.

LINKEDIN PROFILE

Dr. Thorben Bonarius
Regulatory Affairs Expert Pharma- & Biotech
.

LINKEDIN PROFILE

Ivana Krešić
Digital Media
.
.

LINKEDIN PROFILE

Juan Ruiz (MFA)
Graphic Design
.
.

LINKEDIN PROFILE

Dr. Arthur Redpath (BVM&S MRCVS MCIM)
Animal Health Business Development Leader

LINKEDIN PROFILE

Dr. Stefan Stübinger
Innovation & Medical Advisor Cranio-Maxillofacial and Dental Implant Expert

LINKEDIN PROFILE

Paul Hadvary (Dr. scnat ETH)
Chairman/
Board of Directors
.

LINKEDIN PROFILE

Ricardo Cordero (Dr. oec HSG)
Board of Directors
.

LINKEDIN PROFILE

Peter Huber
Board of Directors
.
.

LINKEDIN PROFILE

Ralf Schumacher
Board of Directors
.
.

LINKEDIN PROFILE
alt=""
Portrait of Pascal Winnen

Pascal Winnen (MSc)
Chief Executive Officer/
Quality Assurance/
Board of Directors

LINKEDIN PROFILE
Portrait of Mohamed Hussien

Mohamed Hussien (BPharm, PhD)
Chief Commercial Officer/
Neuroscience

LINKEDIN PROFILE

Maria Kuthning (MSc)
Head of Clinical Operations

LINKEDIN PROFILE
Portrait of Cornelia Baumgartner

Cornelia Baumgartner- Diolaiuti
Clinical Operations Expert/
Oncology

LINKEDIN PROFILE
Portrait of Gheorghe Pop

Gheorghe Nicusor Pop
Biostatician/Medical Monitor

LINKEDIN PROFILE
Portrait of Sandra Müller Lettlova at Hemex AG

Sandra Müller Lettlova (PhD)
Clinical Trial Manager/
Clinical Scientist

LINKEDIN PROFILE
Portrait of Ossama Khalaf (BPharm, PhD)

Ossama Khalaf (BPharm, PhD)
Medical Writer/Grant Expert

LINKEDIN PROFILE
Portrait of Franziska Stemmler

Franziska Stemmler
Business Development

LINKEDIN PROFILE
Portrait of Gabriela Wesolowski

Gabriela Wesolowski
Sales

LINKEDIN PROFILE
Portrait of Frank Stein (Prof. Dr. Dr. h.c.)

Frank Stein (Prof. Dr. Dr. h.c.)
Senior Expert Quality & RA Medical Devices

LINKEDIN PROFILE
Frank Kramer

Dr. Frank Kramer
Clinical Operations Expert/
Cardiology

LINKEDIN PROFILE
Portrait of João Bocas

João Bocas
Wearable Devices Expert

LINKEDIN PROFILE
Portrait of Clive Roper (BSc, PhD, CBiol, CSci, ERT, FRSB)

Clive Roper (BSc, PhD, CBiol, CSci, ERT, FRSB)
Toxicology Expert

LINKEDIN PROFILE
Portrait of Cátia Moutinho

Cátia Moutinho
Medical Writer/
Single-Cell Technology

LINKEDIN PROFILE

Dr. Thorben Bonarius
Regulatory Affairs Expert Pharma- & Biotech

LINKEDIN PROFILE

Sanja Fitzgerald (Dr. Sc. ETH)
Market Access Strategy, Pricing & Reimbursement

LINKEDIN PROFILE
Portrait of Ivana Kresic

Ivana Krešić
Digital Media

LINKEDIN PROFILE
Portrait of Juan Ruiz (MFA)

Juan Ruiz (MFA)
Graphic Design

LINKEDIN PROFILE
Portrait of Dr. Arthur Redpath (BVM&S MRCVS MCIM)

Dr. Arthur Redpath (BVM&S MRCVS MCIM)
Animal Health Business Development Leadern

LINKEDIN PROFILE

Dr. Stefan Stübinger
Innovation & Medical Advisor Cranio-Maxillofacial and Dental Implant Expert

LINKEDIN PROFILE
Portrait of Paul Hadvary (Dr. scnat ETH)

Paul Hadvary (Dr. scnat ETH)
Chairman/Board of Directors

LINKEDIN PROFILE
Portrait of Ricardo Cordero (Dr. oec HSG)

Ricardo Cordero (Dr. oec HSG)
Board of Directors

LINKEDIN PROFILE
Portrait of Peter Huber

Peter Huber
Board of Directors

LINKEDIN PROFILE

Ralf Schumacher
Board of Directors

LINKEDIN PROFILE

We are attending the following conferences

Hemex at 11th Annual Outsourcing in Clinical Trials UK and Ireland 2024 Conference
Hemex at Global Clinical Trials Connect 2024 Conference
Hemex at 14th Annual Outsourcing in Clinical Trials Europe 2024 Conference
Hemex at Swiss Biotech Day Conference 2024
Hemex at Swiss Biotech Day Conference 2024

HEMEX in the media

Convince investors of innovations

At HEMEX, startups receive a podium to present their advanced health care innovations to potential investors in detail and in a small group. From the implant system for the treatment of chronic lymphedema swelling to the method for self-measurement of sleep disorders and therapy for patients with multi-resistant cancers to the technology for combating the causes of periodontitis – four promising young companies took part in the first physical pitch event last year since the outbreak of the pandemic Liestal took part and asked critical questions.

HEMEX receives CHF 7.1 million

HEMEX, partner of the Basel Area Business & Innovation, wants to use the fresh capital to finance initial investments in the early phase of start-ups that are active in the life sciences. The Liestal-based company also plans to recruit new team members for clinical activities, quality assurance and regulatory affairs.

EIC Pathfinder beneficiary HEMEX completes a €6.8 million Series C round

HEMEX, an EIC Pathfinder beneficiary company, has completed another fundraising round. After the first closing in February 2021, they secured a Series C round, increasing the amount to approximately €6.8 million (CHF 7.1 million).

HEMEX banks 7.1 million Swiss Francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company for clinical contract research and investments in start-ups intends to finance firms in their early phase in addition to supporting plans aimed at hiring new team members.

HEMEX attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for HEMEX. The biotech incubator will use the funds to accelerate its global expansion.

HEMEX in the media

Convince investors of innovations

At HEMEX, startups receive a podium to present their advanced health care innovations to potential investors in detail and in a small group. From the implant system for the treatment of chronic lymphedema swelling to the method for self-measurement of sleep disorders and therapy for patients with multi-resistant cancers to the technology for combating the causes of periodontitis – four promising young companies took part in the first physical pitch event last year since the outbreak of the pandemic Liestal took part and asked critical questions.

HEMEX receives CHF 7.1 million

HEMEX, partner of the Basel Area Business & Innovation, wants to use the fresh capital to finance initial investments in the early phase of start-ups that are active in the life sciences. The Liestal-based company also plans to recruit new team members for clinical activities, quality assurance and regulatory affairs.

EIC Pathfinder beneficiary HEMEX completes a €6.8 million Series C round

HEMEX, an EIC Pathfinder beneficiary company, has completed another fundraising round. After the first closing in February 2021, they secured a Series C round, increasing the amount to approximately €6.8 million (CHF 7.1 million).

HEMEX banks 7.1 million Swiss Francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company for clinical contract research and investments in start-ups intends to finance firms in their early phase in addition to supporting plans aimed at hiring new team members.

HEMEX attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for HEMEX. The biotech incubator will use the funds to accelerate its global expansion.

HEMEX in the media

Convince investors of innovations

At HEMEX, startups receive a podium to present their advanced health care innovations to potential investors in detail and in a small group. From the implant system for the treatment of chronic lymphedema swelling to the method for self-measurement of sleep disorders and therapy for patients with multi-resistant cancers to the technology for combating the causes of periodontitis – four promising young companies took part in the first physical pitch event last year since the outbreak of the pandemic Liestal took part and asked critical questions.

HEMEX receives CHF 7.1 million

HEMEX, partner of the Basel Area Business & Innovation, wants to use the fresh capital to finance initial investments in the early phase of start-ups that are active in the life sciences. The Liestal-based company also plans to recruit new team members for clinical activities, quality assurance and regulatory affairs.

EIC Pathfinder beneficiary HEMEX completes a €6.8 million Series C round

HEMEX, an EIC Pathfinder beneficiary company, has completed another fundraising round. After the first closing in February 2021, they secured a Series C round, increasing the amount to approximately €6.8 million (CHF 7.1 million).

HEMEX banks 7.1 million Swiss Francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company for clinical contract research and investments in start-ups intends to finance firms in their early phase in addition to supporting plans aimed at hiring new team members.

HEMEX attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for HEMEX. The biotech incubator will use the funds to accelerate its global expansion.